As of 2025-10-18, the Intrinsic Value of Summit Therapeutics Inc (SMMT) is -1.20 USD. This SMMT valuation is based on the model Peter Lynch Fair Value. With the current market price of 20.99 USD, the upside of Summit Therapeutics Inc is -105.70%.
Based on its market price of 20.99 USD and our intrinsic valuation, Summit Therapeutics Inc (SMMT) is overvalued by 105.70%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -1.20 - -1.20 | -1.20 | -105.70% |
| P/E | (1.63) - (2.72) | (2.06) | -109.8% |
| DDM - Stable | (1.28) - (4.00) | (2.64) | -112.6% |
| DDM - Multi | (0.06) - (0.15) | (0.09) | -100.4% |
| Market Cap (mil) | 15,592.42 |
| Beta | 1.75 |
| Outstanding shares (mil) | 742.85 |
| Enterprise Value (mil) | 15,294.55 |
| Market risk premium | 4.60% |
| Cost of Equity | 13.23% |
| Cost of Debt | 5.00% |
| WACC | 8.45% |